Neuralink to Implant Second Human with Brain-Computer Interface Chip Within a Week

Elon Musk, founder and leader of brain-computer interface startup Neuralink Corp., revealed in a video update on Wednesday that the company plans to implant its brain-computer interface device into a second human patient within about a week. The billionaire-founded startup aims to have a “high single-digit” number of patients implanted with its brain-computer interface chips by the end of this year.

Founder of SpaceX,TeslaIn a widely discussed video recently broadcast on the social media platform X, Elon Musk—wearing multiple hats as CEO and founder-leader of the AI startup xAI—along with several key Neuralink employees, described the current capabilities of their brain-computer interface (BCI) devices and outlined various future possibilities, such as restoring function in cases of paralysis and memory loss. They also detailed the steps that the company’s research team may take in future high-precision surgeries to avoid some of the setbacks encountered after the first BCI chip implantation in Noland Arbaugh, a man from Arizona, USA.

Elon Musk emphasized that the long-term goal is to “mitigate or alleviate the long-term civilizational risks posed by artificial intelligence technology.” “Neuralink can help achieve this long-term objective by creating a tighter ‘symbiotic relationship’ between human intelligence and digital intelligence,” Musk stated, adding that the idea is “to empower certain groups with capabilities beyond their instincts.”

In terms of short-term goals, Neuralink aims to comprehensively assist patients with brain and spinal cord injuries, enabling them to control terminal devices such as smartphones and computers using their thoughts. Neuralink achieves this by implanting a brain-computer interface chip device, known as “Telepathy,” into the human skull. This device, resembling a circular disk with electrode threads, can be successfully embedded into human brain tissue.

Musk stated that in the upcoming surgery, Neuralink will implement significant changes to mitigate the potential issue of electrode threads retracting from brain tissue. The corrective measures proposed by Neuralink include eliminating a step analogous to an “air pocket,” which is a standard component of human brain interface surgeries and may have contributed to thread retraction during the initial procedure. The company aims to implant the threads more precisely into the sulci of the human brain and ensure that the implant sits largely flush with the contour of the skull.

In the video, the Neuralink research team also discussed future next-generation versions of the device. Musk stated that patients with older models should be able to quickly upgrade to newer ones in the future. “It’s like how everyone wants the iPhone 15,” he said. “Not the iPhone 1.”

Near the end of his video presentation, Musk also emphasized Neuralink’s meticulous care for animals used in research. He stated, “We truly do everything we can to maximize the welfare of the animals.” The startup has previously faced criticism for its treatment of animals in laboratory settings.

Elon Musk's Ambitions in the Field of Brain-Computer Interfaces Are Gradually Becoming a Reality

As Neuralink’s multiple groundbreaking research advances drive the successful completion of the first human brain-computer interface (BCI) chip implantation surgery, and its latest video announces plans to implant the BCI device in a second human patient within approximately one week, Elon Musk’s ambitions in the field of brain-computer interfaces are being realized one after another.

Neuralink is a brain-computer interface (BCI) startup founded by Elon Musk, dedicated to developing novel microdevices that enable direct communication between the brain and computers. Since its inception, Neuralink has garnered significant attention in the BCI field for its ambitious goals and innovative technologies. The company has made remarkable progress in multiple areas of brain-computer interface technology, including miniaturization, high-density electrode arrays, and wireless data transmission. Its technology aims to help patients who have lost mobility due to brain or spinal cord injuries to control phones and computers using their brains.

Neuralink recently completed the implantation of its brain-computer interface chip device in its first human patient, marking a significant step forward in the practical application of Neuralink’s technology. The device developed by Neuralink, called “Telepathy,” is a disc-shaped implant placed within the skull, equipped with electrode threads that can be inserted into brain tissue. These electrode threads are capable of recording brain activity and communicating with external devices.

Neuralink’s proprietary technology includes the use of highly advanced, flexible, high-density electrodes and an automated surgical implantation robot, which significantly reduces the complexity of the procedure. The electrode “threads” developed by Neuralink are extremely fine and flexible, minimizing damage to brain tissue during implantation. Neuralink employs a highly precise robot for electrode implantation, capable of inserting electrode filaments with micrometer-level precision, avoiding blood vessels on the brain’s surface, and inserting up to 192 electrodes per minute, thereby substantially enhancing the precision and safety of the surgery.

Over the past six to seven years, backed by hundreds of millions of dollars in investment, Neuralink has developed a comprehensive and leading R&D pipeline for implantable brain-computer interfaces (BCIs) worldwide, positioning itself at the international forefront. Compared with earlier technologies, Neuralink’s technology aims to provide higher-density electrodes and a more precise, minimally invasive implantation procedure. Neuralink’s vision extends beyond medical applications, holding the potential to enhance human cognitive functions and integrate human consciousness with artificial intelligence.

Neuralink has previously projected that it may perform brain-computer interface surgeries on more than 22,000 patients by 2030. The target conditions Neuralink aims to address include limb paralysis, paraplegia, hearing loss, major amputation, and cataracts.

While Neuralink’s advances in brain implants are significant, it is important to note that the technology remains in its early stages. The commercial application of brain-computer interfaces (BCIs), particularly in the medical field, requires stringent regulatory standards and ethical considerations. Some medical experts suggest that technologies such as Neuralink’s implantable BCIs may still require 5–10 years before reaching widespread clinical adoption. Safety, long-term viability, and ease of implantation are key factors determining the success of these technologies in both commercial and medical applications.

Responsible Editor: Yu Jian SF069